The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02077036
Verified February 2014 by Lars Hyllienmark, Karolinska University Hospital. Recruitment status was: Recruiting
The overall aim of the study is to investigate the effect of a new, non-pharmacological method that may alleviate the symptoms of narcolepsy and thereby lead to a reduction in the use of medications with potentially serious side effects in patients with this disease.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
16 Years to 60 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Signed informed consent
Diagnosed with narcolepsy (diagnose code G47.4)
16 - 60 years of age
MSLT has shown hypersomnia (sleeping latency < 8 min) & 1 episode REM
HLA-type associated with increased occurrence of narcolepsy
Reduced cognitive function
Other relevant organ disease (that could affect the study results or put the patient at risk)
Ongoing bacterial infection in the nose
Comorbidity that can increase the risk of bleeding
Has received treatment with an implantable stimulator or other implantable product in the head and / or in the neck
Known pronounced septal deviation
Known allergy to polyvinylchloride or medicinal liquid paraffin
Women not using adequate contraceptives
Participated in a clinical investigational drug trial within the previous 30 days